<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">Coronaviruses cause cytokine release syndrome (CRS) with various degrees in severe patients infected with SARS, MERS and newly discovered virus named SARS-CoV-2. A small clinical trial was performed during SARS-CoV-2 in China that showed tocilizumab that have a good efficacy in blocking the signal transduction pathway of inflammatory protein IL-6 played an important role in CRS. In a related study, Xiaoling 
 <italic>et al.</italic> introduce tocilizumab as an effective drug for rescuing patients with SARS-CoV-2 due to the return of the patient's body temperature to normal and an improvement in respiratory functions 
 <xref rid="b0425" ref-type="bibr">[85]</xref>. In a case report study, Michot 
 <italic>et al.</italic> confirmed that a patient with COVID-19 related respiratory failure can be treated with this drug 
 <xref rid="b0430" ref-type="bibr">[86]</xref>. In this time, there is a phase III clinical trial of tocilizumab, brand-named Actemra for the treatment of adults with severe COVID-19.
</p>
